conference that will make the case for Cosentyx (secukinumab) in a highly competitive market. Cosentyx is a key drug for Novartis, as it is part of the company’s plan to replace lost sales from ...

Gilenya was first approved in 2010 and has been a big brand for Novartis, although it is facing strong competition from newer drugs such as Roche's Ocrevus (ocrelizumab), Merck KGaA's Mavenclad ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...